# Sanofi Completes Acquisition of Blueprint Medicines for Up to $9.5 Billion

> ma · REPORTED · 2025-06-02

Sanofi acquired Blueprint Medicines for up to $9.5 billion, adding a differentiated precision oncology and systemic mastocytosis portfolio to its rare disease franchise. The deal, announced June 2025, brings Blueprint's approved drug avapritinib and its KIT and PDGFRA inhibitor pipeline under Sanofi's umbrella.

About Sanofi / Blueprint Medicines: Blueprint Medicines is a precision therapy company that develops targeted kinase inhibitors for genomically defined cancers and blood disorders, with avapritinib approved for systemic mastocytosis and GIST.

- Company: Sanofi / Blueprint Medicines
- Sector: oncology
- Primary source: https://www.healthcare-brew.com/stories/2025/12/12/2025-biggest-healthcare-deals

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.